This Week in the British Journal of Cancer | GenomeWeb

In the British Journal of Cancer this week, researchers in Massachusetts say there may be therapeutic potential in targeting the EGFR family in patients with epithelial ovarian cancer. Although anti-EGFR therapy has so far proven to have limited benefit against ovarian cancer, recent research shows that activation of ErbB3 may support the growth and proliferation of ovarian cancer cells, and that ErbB3 may serve as a potential therapeutic target for the disease, the authors write.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.